<DOC>
	<DOCNO>NCT01858116</DOCNO>
	<brief_summary>The study evaluate [ 68Ga ] ABY-025 PET image HER2 expression subject HER2-positive HER2-negative breast cancer .</brief_summary>
	<brief_title>PET Study Breast Cancer Patients Using 68GaABY-025</brief_title>
	<detailed_description>Open-labeled , exploratory , single center study . 1 . Group 1 ( dose-finding ) Six subject HER2-positive primary tumor status four subject HER2-negative status . [ 68Ga ] ABY-025 PET low dose ( 100 μg ) ABY-025 peptide perform , follow repeat PET within three week use high dose ( 500 μg ) ABY-025 peptide ( radioactivity maximum 500 MBq ) . A third [ 68Ga ] ABY-025 PET perform HER2-positive subgroup , sign progressive disease find routine clinical evaluation else late 12 month regardless disease status , use ABY-025 peptide dose previously determine preferable . 2 . Group 2 Ten subject HER2-positive primary tumor status . [ 68Ga ] ABY-025 PET perform use ABY-025 peptide dose determine preferable dose-finding part study , follow second [ 68Ga ] ABY-025 PET investigation sign progressive disease else late 9 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Subject &gt; 18 year age 2 . Diagnosis invasive breast cancer metastases 3 . Availability result HER2 status previously determine material primary tumor , either 1 . HER2positive , define DAKO HercepTest™ score 3+ FISH positive 2 . HER2negative , define DAKO HercepTest™ score 0 1+ else ; 2+ FISH negative 4 . Volumetrically quantifiable metastasis lesion CT MRI , least one lesion &gt; = 10 mm small diameter suitable biopsy 5 . ECOG performance status = &lt; 2 6 . Life expectancy least 12 week 7 . Hematological , liver renal function test result within follow limit : White blood cell count : &gt; 2.0 x 10^9/L Haemoglobin : &gt; 80 g/L Platelets : &gt; 50.0 x 10^9/L ALT , ALP , AST : = &lt; 5.0 time Upper Limit Normal Bilirubin = &lt; 2.0 time Upper Limit Normal Serum creatinine : Within Normal Limits else normal clearance 8 . A negative pregnancy test ( serum betahuman chorionic gonadotropin , betaHCG ) screen female patient childbearing potential , must use medically acceptable form contraception study start least 30 day study termination 9 . Subject able participate diagnostic investigation perform study 10 . Informed consent 1 . Manifest second , nonbreast malignancy 2 . Known HIV positive chronically active hepatitis B C 3 . Administration investigational medicinal product within 30 day screen 4 . Ongoing toxicity &gt; grade 2 previous standard investigational therapy , accord US National Cancer Institute 's `` Common Terminology Criteria Adverse Events v4.0 [ CTCAE ] '' 5 . Other ongoing severe disease may influence patient 's ability participate study 6 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>